Teva: Strongs Earnings, $10b Sales in ‘07
Make a commentBy Ed Silverman // February 13th, 2007 // 5:46 am
“Once again, we have proven the strength of our strategies, and our excellence in executing those strategies,” says outgoing ceo Israel Makov. “I truly believe that Teva is ideally positioned to play an even larger role in the health care industry, and capture an even larger share of the opportunities that this industry offers.”
The Israeli generic drugmaker reported net income was $460 million, or 56 cents, up from $305 million, or 45 cents per share, a year earlier. Excluding certain tax-related income and charges, Teva earned $433 million, or 53 cents. Analysts expected 58 cents.
Fourth-quarter sales rose 63 percent to $2.28 billion. Teva expects sales this year to exceed $9 billion and fully diluted earnings to be between $2.07 and $2.19. You can read more here.
[tags]Teva[/tags]